Effectiveness of current interventions in obese New Zealand children and adolescents

Yvonne C Anderson1, Tami L Cave, Vicki J Cunningham

  • 1Department of Paediatrics, Taranaki Base Hospital, David Street, New Plymouth 4310, New Zealand. yvonne.anderson@tdhb.org.nz.

Insights

Mild reductions in body mass index standard deviation scores (BMI SDS) are achievable for obese children and adolescents in New Zealand. Further research is needed to enhance multi-disciplinary programs for better outcomes.

Area of Science:

  • Pediatric Endocrinology
  • Public Health Nutrition
  • Childhood Obesity Interventions

Background:

  • Childhood obesity is a significant public health concern in New Zealand.
  • Various intervention models exist for managing pediatric obesity, including standard care and multi-disciplinary programs.
  • Effectiveness of these interventions requires ongoing evaluation.

Purpose of the Study:

  • To assess the effectiveness of current pediatric obesity interventions in New Zealand.
  • Compare standard care models with established multi-disciplinary programs.
  • Identify factors influencing intervention success.

Main Methods:

  • A prospective study involving 290 children and adolescents (aged 3-16 years) across four New Zealand centers.
  • Data collected over approximately 2.1 years of intervention.
  • Interventions included standard medical care, with or without dietitian/physical activity input, and multi-disciplinary programs.

Main Results:

  • A small but significant annual reduction in BMI SDS was observed across all interventions (-0.15 overall).
  • No significant difference in BMI SDS reduction was found between intervention types.
  • Reduced effectiveness was noted with increasing age at initial attendance; ethnicity and gender had no impact.

Conclusions:

  • Pediatricians play a crucial role in proactively identifying and managing childhood obesity.
  • Current models can achieve modest BMI SDS reductions.
  • Further research is essential to optimize multi-disciplinary programs for improved cardiovascular and metabolic health, alongside BMI SDS.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
399
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
345
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
293